⌘K
After a rebound in UK healthcare equities in 2025, the sector still faces major challenges. In this Hardman Talks, CEO Keith Hiscock is joined by Dr Martin Hall, Head of Life Sciences, to discuss why funding is tight, why commercialisation remains difficult, and what this means for small cap healthcare companies in London. Martin also reflects on key case studies and shares insights from his decades of experience analysing UK life sciences, offering a frank view of the opportunities - and risks - ahead. Watch to understand why the recovery may not tell the full story. Read Martin's 'Hardman & Co Healthcare Index' on our website: https://hardmanandco.com/research/corporate-research/hardman-co-healthcare-index-7/ Important notice: This content has been prepared purely for information purposes, and should not be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The companies or legal entities covered in this content may or may not pay us a fixed fee for this content to be made available. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment, and the securities or legal entities mentioned in this content may not be suitable or appropriate for all investors. Each investor’s particular needs, investment objectives and financial situation were not taken into account in the preparation of this content. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this content various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances. For more information, please read our full disclaimers: www.hardmanandco.com/research-disclosures www.hardmanandco.com/disclaimer
